Abstract

Introduction

In industrialized countries, endometrial cancer (EC) represents the most common malignancy of the female reproductive tract. The precursor lesion for endometrioid adenocarcinoma of the endometrium, which comprises the majority of ECs, is endometrial hyperplasia (EH). EH is a noninvasive, abnormal proliferation of the endometrial lining of the uterus and associated with a significant risk of concurrent EC or progression to EC. The leading symptoms of EH are bleeding disorders in premenopausal women and vaginal bleeding in postmenopausal women. The most important risk factor is chronic exposure to unopposed estrogen. This narrative review aims to give an overview of the classification, risk factors, and management of EH. We searched the following databases: PubMed and Cochrane Controlled Trials register. We performed the final search in March 2021. Additionally, we performed a systematic literature search of the databases PubMed and Cochrane Controlled Trials register for studies analyzing the efficacy of progestin treatment in women with EH.

Classification of EH and risk of progression to EC

Histologically, EH describes the abnormal proliferation of endometrial glands with a greater gland-to-stroma-ratio than healthy proliferative endometrium but without endometrial stromal invasion. Diagnosis should be based upon histological assessment of a tissue sample obtained by endometrial biopsy, curettage, or hysterectomy. The most widely used classification system for EH is the 2014 World Health Organization (WHO) Classification System which differentiates between:

• EH without atypia (benign EH) and

• atypical EH/endometrial intraepithelial neoplasia (EIN).

This distinction is particularly important because clinical management of the two conditions is different, depending on the presence or absence of nuclear atypia. Nuclear atypia is defined as nuclear enlargement with or without prominent nucleoli [1]. EH without atypia constitutes a benign lesion without significant somatic genetic changes caused by extensive exposure to estrogen that is not counterbalanced by the protective effects of progestins. If physiological progesterone levels are resumed or if therapeutic progestins are used, the hyperplastic changes regress and the endometrium becomes healthy again in the majority of cases [2]. EH without atypia seems to rarely progress to EC although evidence supporting this statement is poor. For example, in a case series published in 1985, benign EH only progressed to EC in two (1.6%) out of 122 patients. The first patient with simple hyperplasia developed atypical EH and subsequently EC 11 years after the first diagnosis of EH. The second patient had complex EH which progressed to EC 8.3 years after the initial diagnosis. Neither patient had received progestin treatment or died of their disease [3].

In a case–control study nested in a cohort of 7,947 women diagnosed with EH from 1970 to 2002, 138 women were diagnosed with EC, on average 6 years after the initial diagnosis of EH [4, 13]. The cumulative 20-year progression risk was less than 5% for EH without atypia but 28% for atypical EH. Specifically, for EH without atypia, the cumulative progression risk increased from 1.2% (95% CI, 0.6% to 1.9%) to 1.9% within 4 years (95% CI, 1.2% to 2.6%), to 4.6% within 9 years (95% CI, 3.3% to 5.8%) and up to 19 years after EH diagnosis. For women with atypical EH, the cumulative risk increased from 8.2% (95% CI, 1.3% to 14.6%) to 12.4% within 4 years (95% CI, 3.0% to 20.8%), to 27.5% within 9 years (95% CI, 8.6% to 42.5%) and up to 19 years after the diagnosis of EIN.

Atypical EH has many similarities with endometrioid EC at the molecular level [4]. Concurrent EC was found in 37% of women with atypical EH in a retrospective case series including 219 patients with EIN combined with a review of 31 published studies including a total of 2571 patients [5]. Other studies have documented a risk of concomitant EC in up to 50% of patients with atypical EH [6–9]. A high risk of concomitant EC among women with atypical EH is also consistent with the high risk of progression to EC observed among women with EH undergoing progestin treatment. This risk of progression to EC has been described to be between 15 and 28% [10–12]. For example, a retrospective cohort study investigated 242 women with atypical EH, of whom 74% received progestin therapy [12]. The rate of progression to EC was significantly higher without progestin treatment (101.4 versus 20.5 per 1000 woman-years). During a median follow-up of five years, 15% of all women with atypical EH developed EC. The risk for development of EC in women with atypical EH has been shown to be diminished approximately threefold to fivefold when treated with progestin [12]. Another important issue to be considered when assessing the concurrent or future risk of EC among women with atypical EH is the fact that it may be difficult to histopathologically distinguish EIN from EC. Illustrating these diagnostic difficulties, Trimble et al. found over- or underdiagnosis in almost every third specimen [13]. Specifically, independent gynecologic pathologists reviewed 289 endometrial biopsy specimens from women with a community diagnosis of atypical EH and found that in 25% the diagnosis was less severe than atypical EH, whereas in 29.1% EC was already present. This suggests a significant overlap between the different diagnoses of EH without atypia, atypical EH, and EC both in clinical practice as well as in the literature. Therefore, it is reasonable to treat atypical EH as the equivalent of early EC when counseling affected patients.

Risk factors of EH

As its precursor lesion, the risk factors for developing EH are closely related to the well-known risk factors for endometrioid adenocarcinoma of the endometrium. The most important risk factor for both EH and EC is a chronic imbalance of estrogen and progestin in favor of estrogen [14–18]. Exposure to excessive estrogen without the protective effect of progestin can be endogenous or exogenous in nature. Other risk factors include genetic factors such as hereditary nonpolyposis colorectal cancer (HNPCC, or Lynch syndrome) and Cowden syndrome, which is rare and in most cases related to a mutation in the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) gene, located on chromosome 10q23.31 [19–22].

Endogenous estrogen exposure

Examples of excessive endogenous exposure to estrogen include obesity, chronic anovulation, early menarche, and late menopause as well as the presence of estrogen-secreting tumors. In obese women, a high amount of adipose tissue is closely associated with higher local and circulating levels of estradiol. This can be explained through various mechanisms. Firstly, an increase in adrenal secretory activity is often observed, which leads to an increase in androgen precursors. These precursors may then be converted to estradiol in peripheral tissues. Secondly, the conversion rate of androstenedione to estrone by the enzyme aromatase rises as this conversion primarily takes place in adipose tissue. Lastly, higher concentrations of estradiol can be found in obese patients as plasma levels of estradiol-binding sex hormone-binding globulin (SHBG) are typically depressed in this patient population [23]. These pathophysiological observations are consistent with clinical findings. For example, in a retrospective cohort study including 916 premenopausal women with abnormal uterine bleeding, patients with a body mass index of over 30 kg/m² developed complex hyperplasia or EC 4 times more often than lean women (95% CI, 1.36–11.74) [24].

Chronic anovulation is another important risk factor for EH. When anovulation occurs, sex hormone production is not cyclical as in regularly ovulating premenopausal women. Without ovulation, estrogen levels still dominate without the opposing effect of progesterone produced by the corpus luteum after ovulation. This imbalance leads to a continued proliferation of the endometrium resulting in a higher risk of developing EH and eventually endometrioid EC. Common settings associated with anovulation include polycystic ovary syndrome (PCOS), hyperprolactinemia, and perimenopausal hormonal status. In 2009, a meta-analysis of four case–control studies including a total of 4056 women showed an almost threefold risk of developing EC for women with PCOS compared to the general population (OR 2.70, 95% CI, 1.00–7.29) [25]. In 2012, a subsequent meta-analysis of the same studies including another cross-sectional study, confirmed this risk elevation in PCOS patients (OR 2.89, 95% CI, 1.52–5.48) [26]. However, these results need to be interpreted with caution since other authors suspected that the risk increase was exaggerated due to risk factors commonly associated with PCOS such as obesity and diabetes and skewing of the risk estimates due to a potential selection bias in some of the studies [27, 28].

Hormone-secreting tumors can cause an endogenous sex hormone imbalance. For example, granulosa cell tumors represent potentially estrogen-secreting tumors of the ovary. Consequently, EH is diagnosed in 25% to 50% of women with granulosa cell tumors of the ovary [29, 30]. If EH is diagnosed in a patient without other known risk factors, estrogen-secreting tumors should therefore be excluded.

Management of EH

A number of different aspects should be considered in the treatment of EH. Depending on the histological features and the patient´s medical history, all established risk factors for progression to EC or the concurrent presence of the disease should be determined. In addition, a specialized gyneco-pathologist should be consulted given the diagnostic uncertainties of differentiating between EH, atypical EH, and EC. The 2014 WHO classification of EH for the two—EH without atypia (benign EH) and atypical EH—should be applied in order to guarantee comparability of histopathological data both in clinical practice and in academic studies. The presence or absence of nuclear atypia is the most important factor for appropriate therapy planning and monitoring. EH is mostly associated with excessive exposure to unopposed estrogen. It is therefore crucial to supplement any form of treatment by removing the source of excessive estrogen, for example, by encouraging obese patients to lose weight, stopping any type of unopposed estrogen therapy, treating anovulation (e.g., in PCOS patients or patients with hyperprolactinemia), or identifying and removing estrogen-secreting tumors. Additionally, it is important to consider the necessity of contraception and fertility issues in premenopausal EH patients, depending on their family planning status. The most important treatment options for EH can be divided into three subgroups:

1. Surveillance (watchful waiting)

2. Surgical treatment (hysterectomy±bilateral salpingo-oophorectomy)

3. Progestin therapy

Progestin therapy

Multiple studies support the efficacy of progestins in treating both benign and atypical EH [59–64]. Progestin therapy is therefore the most widely used approach for treating women with EH. The progestin supply activates progesterone receptors, which leads to decidualization of the endometrial stroma and subsequently to endometrial thinning [2]. Especially in premenopausal women with benign EH and a desire to preserve fertility, progestin administration should be the therapy of first choice. When a high risk of concurrent EC is suspected, initial endometrial biopsy should be supplemented with a dilation and curettage procedure to exclude any malignancy. Progestin therapy is contraindicated in patients with thrombophilia, hormone receptor-positive breast cancer, liver failure, known allergy to progestins and during pregnancy.

Different types of progestins and different routes of administration have been proven to be effective in treating EH. While orally administered megestrol acetate and medroxyprogesterone acetate (MPA) were formerly the most widely used therapeutics, the levonorgestrel-releasing intrauterine device (LNG-IUD), which releases 20 μg of LNG over 24 h (LNG 52/5) for a period of 4 to 5 years, has replaced oral progestin therapies as current first-line therapy in many countries. Indeed, in patients with benign EH, regression to healthy endometrium has been reported in up to 90% upon treatment with the LNG 52/5 IUD [65, 66]. In women with atypical EH and/or early EC, treatment with the LNG 52/5 IUD has been shown to lead to complete regression in approximately 75–85% of patients [2]. Randomized trials reported that the LNG 52/5 IUD is more effective than orally administered progestins in the treatment of EH, while having fewer systemic side effects and providing effective contraception [67–69]. Through its local effect on the endometrium, the LNG 52/5 IUD evades absorption and metabolism by the intestinal flora and the liver, where progestin is associated with sedative effects [70, 71]. Other side effects of orally administered progestins include bloating, nausea, headaches, and mood swings or even depression. Irregular vaginal bleeding patterns, including spotting, represent another typical side effect of progestin treatment. This is true for both oral and intrauterine treatments. A meta-analysis of 34 observational studies found no difference in vaginal bleeding irregularities in women treated with oral progestins as compared with women who received the LNG 52/5 IUD [72].

Although potentially more effective, the LNG 52/5 IUD might not constitute an appropriate therapeutic approach for all patients with EH. Oral progestins might be a better option for women who are eager to have children, patients with IUD-related dysmenorrhea, or anatomic factors complicating IUD placement. When treating EH with oral progestins, patients should receive a continuous therapeutic dose over three to six months. Therapeutics include progestin monotherapies and combined estrogen-progestin drugs (oral contraceptives). As previously mentioned, the most common oral progestin monotherapeutics are megestrol acetate and MPA [64, 65]. The doses of MPA used in the literature depend on the type of EH and vary from 10 mg per day for benign EH to 600 mg per day in EIN [73]. Overall, in order to treat EIN progestin therapy should be administered continuously and in higher doses than for treatment of benign EH [66, 74–76]. Moreover, cyclic progestin therapies are more frequently associated with vaginal bleeding irregularities than continuous dosing.

However, these medications do not provide contraception. As progestin medications are contraindicated during pregnancy, additional birth control should be advised to premenopausal women using these therapies. To date, no high-quality data supporting the use of oral contraceptives in the treatment of EH are available, although the effect of progesterone dominates at the tissue site in combined estrogen-progestin drugs [77].

The therapeutic success of progestin therapy should be monitored by endometrial sampling on a 3-monthly or 6-monthly basis. Especially in women with atypical EH a thorough follow-up is mandatory. If regression to a healthy endometrium can be demonstrated histologically, premenopausal patients who would like to preserve fertility may end progestin therapy after 3 to 6 months and try to become pregnant. In fact, after successfully completing progestin therapy, some women with EH are able to conceive. A meta-analysis including 28 studies with a total of 1038 patients with atypical EH or early EC reported that 34% of patients conceived after progestin treatment (95% CI, 30–38%) and 20% of these women actually delivered a baby [73].

In postmenopausal women or premenopausal women without an immediate desire to become pregnant, progestin therapy should be continued as maintenance therapy with further follow-up via endometrial sampling, especially if vaginal bleeding abnormalities recur [78, 79]. If atypical EH persists or if EC develops despite continued progestin therapy, hysterectomy is recommended.

Systematic literature search “efficacy of progestin treatment in women with EH”

We performed a literature search of the databases PubMed and Cochrane Controlled Trials register (search date 30–06-2020) using the search terms: ((((("progestinic"[All Fields] OR "progestinics"[All Fields]) OR "progestins"[Pharmacological Action]) OR "progestins"[MeSH Terms]) OR "progestins"[All Fields]) OR "progestin"[All Fields]) AND (("endometrial hyperplasia"[MeSH Terms] OR ("endometrial"[All Fields] AND "hyperplasia"[All Fields])) OR "endometrial hyperplasia"[All Fields]) AND (((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "therapy"[MeSH Subheading]) OR "therapy"[All Fields]) OR "treatment"[All Fields]) OR "treatment s"[All Fields]). This search yielded 749 citations. We then restricted the search to the last 20 years (January 2000 to June 2020) resulting in 385 citations. The abstracts of these publications were screened and 33 of them were selected that included original data from retrospective or prospective comparisons of endocrine treatment options with progestins compared to placebo or no treatment. These studies were retrieved in full and a reference search was performed, yielding an additional 3 citations. In summary, we identified 7 systematic reviews and/or meta-analyses [65, 66, 72, 73, 80–82], 21 cohort studies [59, 61, 74–76, 78, 79, 83–96], 1 case–control study [60], 6 randomized controlled trials [97–102], and one case report [103]. Table 1 shows the study characteristics and results of the 6 randomized clinical trials with patient-specific data analyzing the efficacy of progestin treatment in women with EH. Table ​Table22 shows the study characteristics and results of the 21 cohort studies with patient-specific data analyzing the efficacy of progestin treatment in women with EH.

Table 2

Patient characteristics and results of prospective and retrospective cohort studies analyzing the efficacy of progestin treatment in women with EH

Author	Year	Study type	Number of patients	Population characteristics	Intervention	Regression of EH	Persistence/progression of EH	Side effects
Reed [59]	2009	CS	185	Complex (n=115) or atypical EH (n=70) on independent pathology review	Progestin therapy (oral MPA or MGA or NETA) or no therapy	Complex EH: 59% (68/115) with progestins vs. 12% (14/115) with no therapy; Atypical EH: 54% (38/70) with progestins vs. 8% (6/70) with no therapy	28.4% with progestins vs. 30% with no therapy (complex EH); 26.9% with progestins vs. 66.7% with no therapy (atypical EH); EC G1 in 11/28 follow-up hysterectomies	–
Dhar [61]	2005	CS	4	Endometrioid EC, G1, PR positive	LNG-releasing IUD for at least 6 months	1/4	3/4	IUD expulsion (n=3); emergency curettage (n=1)
Wildemeersch [83]	2003	CS	12	Simple EH (n=7), EH with atypia (n=5)	LNG-releasing IUD (14 µg/d) for at least 12 months	12/12	One patient developed EC, G1, which regressed in consecutive biopsies	–
Mandel-Baum [84]	2020	CS	245	Atypical hyperplasia on in-house pathology report	Oral progestin therapy (n=140 MGA; n=28 MPA; n=8 others) or LNG-IUD (n=69) for at least 1 month	78.7% (LNG-IUD) vs. 46.7% (systemic progestins)	Progression to EC: 4.5% (LNG-IUD) vs. 15.7% (systemic progestins)	Morbidly obese women had higher benefit from LNG-IUD (HR 4.72; 95% CI 2.83–7.89) for CR)
Marra [75]	2014	CS	132	EH without atypia (simple or complex)	Oral progesterone in 2nd half of menstrual cycle for 18 months or no treatment	95% vs. 75%, p=0.05, for simple EH; 89% vs. 35%, p<0.001, for complex EH	Regression rates were dose-dependent: 82%, 98%, and 100% for 100 mg, 200 mg and 300 mg	–
Simpson [76]	2014	CS	44	Atypical EH (n=19), EC G1 (n=25)	Oral progestin therapy (n=140 MGA; n=28 MPA; n=8 others) or LNG-IUD (n=69) for at least 1 month	24/44 (55%)	20/44 (45%); 13/44 with regression later recurred; 3/44 were up-staged	–
Park [79]	2013	CS	48	EC G1 with superficial myometrial invasion or EG G2/3 with no myometrial invasion	Oral progestin therapy (n=14 MGA; n=34 MPA) for a median of 6 months	37/48 (77%)	16/37 (43%)	Median time to CR 17 weeks; No mortality; 10 live births
Park [78]	2013	CS	33	Recurrence after progestin treatment for EC G1: atypical EH (n=13), EC G1 (n=20)	Oral progestin therapy (n=3 MGA; MPA; n=30) for a median of 6 months	28/33 (85%)	5/33 (15%)	No mortality
Wildemeersch [85]; Update of [83]	2007	CS	20	Simple EH (n=12), EH with atypia (n=8)	LNG-releasing IUD (20 µg/d) for at 14–90 months	11/12	1/12 had persisting benign EH	–
Yang [86]	2019	CS	160	atypical EH (n=120), EC stage I without myometrial invasion (n=40)	Hysteroscopic resection+oral progestin therapy until CR	148/160 (93%)	4/160 (2%)	15 of 60 attempting pregnancy became pregnant
Pal [74]	2018	CS	32	atypical EH (n=17), EC G1/2, stage I (n=15)	LNG-IUD for 6 months	80% (atypical EH) vs. 67% (EC G1) vs. 75% (EC G2)	3/32	1/5 became pregnant and delivered
Scarselli [87]	2010	CS	34	EH without atypia (n=30), atypical EH (n=4)	LNG-IUD (20 µg/day) for 5 years (range 12–60 months)	32/34	2/32 persistence; after mean follow-up of 17 years 9 had hysterectomy with EH in 5/9 cases
Buttini [88]	2009	CS	57	EH without atypia (n=41), EH with atypia (n=16)	LNG-IUD (n=26), oral progestin (n=10), hysterectomy (n=21)	21/26 (LNG-IUD) vs. 9/10 (progestin)	2/32 persistence; 0/57 developed EC	1 LNG-IUD removed for side effects
Varma [89]	2008	CS	105	EH without atypia (n=96), EH with atypia (n=9)	LNG-IUD for 2 years	96% (90/94) after 1 year; 90% (94/105) after 2 years; 88/96 (92%) for EH without atypia and 6/9 (67%) for EH with atypia	1 case of EC	–
Gallos [90]	2013	CS	344	Complex EH without atypia or EH with atypia	Oral progestins (n=94) or LNG-IUD (n=250)	95% (237/250) for LNG-IUD vs. 84% (79/94) for oral progestins (OR 3.04; 95% CI 1.4–6.8)	8 cases of EC	Hysterectomy rates were 55/250 (22%) for LNG-IUD vs. 35/94 (37%) for oral progestins
Gallos [91]; Update of [90]	2013	CS	219	Complex EH without atypia or EH with atypia who achieved CR after progestin treatment	Oral progestins or LNG-IUD	–	21/153 (14%) for LNG-IUD vs. 20/66 (30%) for oral progestin; 2 cases of EC	Hysterectomy rates lower for LNG-IUD (20% vs. 32%)
Cholakian [92]	2016	CS	60	EH with atypia (n=25); EC G1 (n=35)	MGA (n=42); MPA (n=11); LNG-IUD (n=22); multiple regimens possible	–	–	Median weight change greater for MGA vs. LNG-IUD (+2.9 vs.+0.05 kg); BMI<35 gained more weight vs. BMI≥35 (+2.3 vs. − 0.7 kg/month); for BMI≥35, MGA had more weight gain than LNG-IUD (+2.2 vs. − 5.4 kg)
Kim [93]	2016	CS	75	EH without atypia (n=60); EH with atypia (n=15)	LNG-IUD for 12 months	95% (36/38) after 12 months	1 case with residual EH	–
Marnach [94]	2017	CS	94	Endometrial intraepithelial neoplasia	LNG-IUD	87% (no atypia); 62% (with atypia); 22% (adenocarcinoma)	–	–
Haoula [95]	2011	CS	51	EH without atypia (n=32); EH with atypia (n=19)	LNG-IUD for 12 months	97% (31/32) for EH without atypia after 24 months; 84% (16/19) for atypical EH	2 cases of persistence	–
Kim [96]	2013	CS	16	EC G1,<2 cm	LNG-IUD+oral MPA (500 mg/day) for 3 months	88% (14/16); median time to CR 9.8 months	No case of progression	No treatment-related complications
Pooled analysis	-	CS (n=21 including two Updates)	1087	–	–	LNG-IUD with higher rates vs. oral progestins in 7 studies	Progression to EC lower with LNG-IUD in 2 studies; regression rates dose-dependent with oral progestins in 1 study	Hysterectomy rates lower for LNG-IUD in 2 studies; more weight gain for MPA/MGA than LNG-IUD in 1 study

Open in a separate window

EH, endometrial hyperplasia; CS, cohort study; MPA, medroxyprogesterone acetate; MGA, megestrol acetate; NETA, norethisterone acetate; EC, endometrial cancer; G1, grading 1; LNG, levonorgestrel; IUD, intrauterine device; PR, progesterone receptor; RCT, randomized controlled trial; BMI, body mass index; CR, complete response.

EH, endometrial hyperplasia; CS, cohort study; MPA, medroxyprogesterone acetate; MGA, megestrol acetate; NETA, norethisterone acetate; EC, endometrial cancer; G1, grading 1; LNG, levonorgestrel; IUD, intrauterine device; PR, progesterone receptor; RCT, randomized controlled trial; BMI, body mass index; CR, complete response.

In addition to the RCTs and CS listed in Tables ​Tables11 and ​and2,2, we identified 1 case–control study [60] and 1 case report [103]. In the case–control study, Montz et al. assessed the feasibility of using a. LNG-IUD to treat presumed FIGO stage IA, grade 1 EC in women at high risk for perioperative complications, i.e. American Society of Anesthesiologists class III or IV. Twelve patients have been followed up to 36 months; results of biopsies were negative in 7 of 11 at 6 months and 6 of 8 at 12 months. No IUD-related complications, except for expulsion, occurred. Sixteen complications (one fatal) occurred in 9 of the 15 control patients who underwent surgery. The authors conclude that LNG-IUD is a feasible treatment with special relevance for patients with early EC and a high risk of surgical complications. In the case report, Kresowik et al. report a patient with atypical endometrial hyperplasia who developed an adenocarcinoma of the endometrium after 6 months of treatment with a LNG-IUD. The authors advocate caution when using this therapy and recommend rigorous and in-depth shared decision making.

Table 1

Patient characteristics and results of randomized controlled trials analyzing the efficacy of progestin treatment in women with EH

Author	Year	Study type	Number of patients	Population characteristics	Intervention	Regression of EH	Persistence/pro-gression of EH	Side effects
Dolapcioglu [97]	2013	RCT	104	simple EH (n=61), atypical EH (n=43)	Oral MPA (10 mg/day; n=52) vs. LNG-IUD (n=52) both for 3–6 months; 2-year follow-up	64% (MPA) vs. 100% (LNG-IUD) after 6 months	22/51 (43%) for MPA vs. 4/51 (8%) for LNG-IUD after 2 years; 50% (MPA) vs. 84% (LNG-IUD) after 3 months	–
Orbo [98]	2008	RCT	258	EH without further differentiation	LNG-IUD vs. oral progestin, observation for 6 months; follow-up for 24 months	LNG-IUD more effective vs. oral progestins and observation after 6 months (p=0.001) and after follow-up	No case of EC during follow-up (56 to 108 months)	–
Ismail [99]	2013	RCT	90	EH without atypia	Cyclical MPA 10 mg/day vs. cyclical NETA 15 mg/day vs. LNG-IUD for 6 months	36.6% vs. 40% vs. 66.7%	No case of EC	–
Karimi-Zarchi [100]	2013	RCT	40	EH without atypia	Cyclical MPA 20 mg/day vs. LNG-IUD for 3 months	LNG-IUD more effective (p<0.05)	–	Better satisfaction; less side effects with LNG-IUD
El-Behery [101]	2015	RCT	138	EH without further differentiation; diagnosed by ultrasound	Oral dydrogesterone vs. LNG-IUD for 6 months	LNG-IUD more effective (96% vs. 80%)	Recurrence rate lower with LNG-IUD (0% vs. 12%)	Patient satisfaction better with LNG-IUD despite more spotting
Orbo [102]; Update of [98]	2016	RCT	153	EH without further differentiation	LNG-IUD vs. oral progestin vs. observation for 6 months; follow-up for 24 months	–	Histological recurrence in 55/135 (41%) with CR; Recurrence rates similar in three therapy groups; recurrence dependent on menopausal status (p=0.0005) and estrogen level (p=0.0007)	–
Pooled analysis	–	RCT (n=6 including one Update)	783	–	–	LNG-IUD with higher rates vs. oral progestins in all studies	LNG-IUD with lower rates of persistence/recurrence in 2 studies	Less side effects with LNG-IUD in 1 study; better patient satisfaction in 2 studies

Open in a separate window

Systematic reviews of progestin treatment for EH or early EC

In a systematic review and meta-analysis of 7 randomized trials with 766 patients, Abu Hashim et al. found that the LNG-IUD achieved a higher regression rate than oral progestins after 3, 6, 12, and 24 months (OR, 7.46; 95% CI, 2.55–21.78). Subgroup analysis showed that the effect of treatment with the LNG-IUD was superior for both simple and complex EH [65]. In another systematic review and meta-analysis including 24 observational studies and 1001 patients, Gallos et al. confirmed the superiority of the LNG-IUD to oral progestins both for complex EH (pooled regression rate, 66% vs 92%; p<0.01) and atypical EH (pooled regression rate, 69% vs 90%; p =0.03) [66]. In a second meta-analysis of 34 observational studies, Gallos et al. investigated the efficacy of conservative treatment in women with early EC (408 patients) or atypical EH (151 patients) [72]. Endocrine treatment achieved a pooled regression rate of 76%, a relapse rate of 41%, and a live birth rate of 28%. Twenty women were diagnosed with ovarian cancer (concurrent or metastatic) during follow-up (4%) and 10 progressed to higher than stage I EC (2%), among whom 2 women died. These data show that endocrine treatment of early stage EC is feasible, but is associated with a significant morbidity and mortality, which can be estimated at around 1 in 200. Wei et al. found a similar efficacy of progestins in women with EC G1 or atypical EH summarizing 28 studies with 1038 patients [73]. Specifically, women with EC G1 or atypical EH had a pooled rate of complete regression (CR) of 71%. Although 34% of women became pregnant, only 20% of them delivered live newborns. The CR rate for women using progestin plus IUD was higher than for IUD alone (87% versus 76%).

A Cochrane meta-analysis compared oral and intrauterine progestins for atypical EH and included only one randomized trial in which a levonorgestrel-releasing intrauterine device (LNG-IUD) was found to be superior to oral medroxyprogesterone acetate (MPA) [82]. In a more recent systematic review and meta-analysis, this finding was confirmed by Yuk et al. [75]. That meta-analysis included five RCTs with 377 patients. Here, the regression rate in women using the LNG-IUD was higher than for oral MPA among lean women (relative risk [RR] 1.41; 95% CI 1.23–1.62), whereas the two regression rates, for LNG-IUD and oral MPA, were similar among obese women (RR 1.03; 95% CI 0.94–1.13). The LNG-IUD treatment was also superior in nonatypical EH (RR 1.36; 95% CI 1.07–1.73) and mixed EH (atypical and non-atypical) (RR 1.44; 95% CI 1.21–1.71).

There is weak evidence from a meta-analysis of two RCTs with 59 patients that metformin may be equally as effective as megestrol acetate (MGA) for the treatment of EH [76].

Conclusion

In summary, the available data from individual studies (Table ​(Table1)1) and meta-analyses clearly show that progestins are a safe and very effective treatment in patients with EH without atypia. In these patients, oral progestins achieve regression rates of around 85% and the LNG-IUD achieves regression rates of up to 100%. In contrast, the efficacy of progestins is significantly lower in patients with atypical EH or EC G1. In these patients, regression rates between 70 and 85% may be expected and recurrence rates are high at to 40%. Treatment with the LNG-IUD seems to be more effective than oral progestins in patients with atypical EH or EC G1. The rates of live births after treatment are low at around 20%. Obese women gain more benefit from progestin treatment due to the higher relative background risk, but the treatment efficacy of progestins is higher in lean women. Additionally and notably, endocrine treatment of atypical EH or EC G1 carries a clinically relevant risk of mortality, which can be estimated as 1 in 200. Therefore, patients with atypical EH or EC G1 attempting treatment with progestins should be made aware of the low live-birth rates, the high recurrence risk, and the mortality associated with this kind of treatment. The standard of care for patients with atypical EH or EC G1 remains total hysterectomy.

Author contribution

L.K.N. and C.B.T. performed the literature research and wrote the manuscript with support from M.W. All authors contributed to the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Declarations

Footnotes

References